Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Structure Therapeutics (GPCR) aims to replace expensive injectable biologics and peptides with inexpensive oral small molecule medicines. Biologics and peptides present with numerous challenges - they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results